Bridgewest Group has announced its acquisition of Pfizer's sterile injectable manufacturing facility in Perth, Australia, aiming to enhance its pharmaceutical portfolio and capitalize on the growing demand for drug products globally.

Target Information

Bridgewest Group has signed a definitive agreement to acquire the sterile injectable manufacturing facility of Pfizer (Perth) Pty Ltd, a subsidiary of Pfizer, Inc. This cGMP-certified facility, located in the Bentley suburb of Perth, Western Australia, is approved to supply drug products in over 90 countries globally. Regulatory bodies including the FDA, TGA, and EU have granted necessary approvals for its diverse range of sterile injectable essential drug products and specialty oncology drug products.

The acquisition includes not only the operations of the facility but also a suite of drug products that Bridgewest Group intends to market and expand globally. This strategic move builds on Bridgewest's previously successful acquisition and transformation of Hospira Adelaide Pty Ltd into BioCina, a flourishing contract development manufacturing organization (CDMO). The Perth facility will operate independently from BioCina, emphasizing Bridgewest Group's commitment to pharmaceutical manufacturing in Australia.

Industry Overview

The pharmaceutical manufacturing industry in Australia is characterized by a robust framework supported by innovative research and development. The Australian government has proactively im